Ocuphire Pharma Return On Equity vs. Current Valuation

OCUPDelisted Stock  USD 1.13  0.06  5.04%   
Based on the key profitability measurements obtained from Ocuphire Pharma's financial statements, Ocuphire Pharma may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Ocuphire Pharma's ability to earn profits and add value for shareholders.
For Ocuphire Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ocuphire Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ocuphire Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ocuphire Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ocuphire Pharma over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Please note, there is a significant difference between Ocuphire Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocuphire Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocuphire Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Ocuphire Pharma Current Valuation vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Ocuphire Pharma's current stock value. Our valuation model uses many indicators to compare Ocuphire Pharma value to that of its competitors to determine the firm's financial worth.
Ocuphire Pharma is considered to be number one stock in return on equity category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Ocuphire Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Ocuphire Current Valuation vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Ocuphire Pharma

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.36
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Ocuphire Pharma

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
(6.57 M)
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Ocuphire Current Valuation vs Competition

Ocuphire Pharma is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 5.4 Billion. Ocuphire Pharma has negative current valuation of (6.57 Million) having no influence on the industry.

Ocuphire Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Ocuphire Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ocuphire Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Ocuphire Pharma's change in net profit over the period of time. It can combine multiple indicators of Ocuphire Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan. Ocuphire Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.

Ocuphire Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Ocuphire Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ocuphire Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ocuphire Pharma's important profitability drivers and their relationship over time.

Use Ocuphire Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ocuphire Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ocuphire Pharma will appreciate offsetting losses from the drop in the long position's value.

Ocuphire Pharma Pair Trading

Ocuphire Pharma Pair Trading Analysis

The ability to find closely correlated positions to Ocuphire Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ocuphire Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ocuphire Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ocuphire Pharma to buy it.
The correlation of Ocuphire Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ocuphire Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ocuphire Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ocuphire Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Ocuphire Pharma position

In addition to having Ocuphire Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Moderate Funds Thematic Idea Now

Moderate Funds
Moderate Funds Theme
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Consideration for investing in Ocuphire Stock

If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets